Work

Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.3107

Authors: Shiraj Sen, David Sommerhalder, Anthony W. Tolcher, Crystal Miller, David D. Stenehjem, Michael Carleton, Philippe Pultar, Timothy A. Yap

Institutions: Aprea Therapeutics, Inc. (United States), University of Minnesota, Duluth, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162535355

Cites:

Cited by:

Related to: